Experimental gene therapy extends lifespan of mice suffering from untreatable mitochondrial disease

NewsGuard 100/100 Score

Researchers at the University of Helsinki and Folkhälsan Research Center have, together with their collaborators, for the first time demonstrated in a mouse model that partial restoration of respiratory chain function in mitochondria, which serve as cellular power plants, may be sufficient to entirely prevent symptoms of a severe mitochondrial disorder.

The model employed in the study was based on the cross-breeding of two mouse strains: one developed by Professor Vineta Fellman's research group, carrying the human GRACILE syndrome patient mutation, and mice expressing alternative oxidase (AOX), which was provided by Professor Howard Jacobs and Dr Marten Szibor. GRACILE syndrome is a currently untreatable mitochondrial disease belonging to the Finnish disease heritage.

Mammals do not normally have the AOX gene, but since mitochondria are so similar in all organisms, it maintains its function even after being transferred from a sea squirt (Ciona intestinalis) to mice. AOX is a mitochondrial enzyme that has the ability to improve electron flow in the respiratory chain when a part of the chain, complex III in this case, becomes dysfunctional due to a disease-causing mutation.

In the recently published study, the research group headed by Professor Fellman and Docent Jukka Kallijärvi found out that a fatal cardiac disease did not develop at all in mice carrying the AOX transgene. Subsequently, the mice lived three times longer than the control group. Furthermore, AOX improved their kidney disease and brain cell changes.

"The AOX transgene extended the lifespan of the mice dramatically by enhancing respiration in the tissues that require the most energy, such as the heart. Of course, such a transgene cannot be used to treat humans, but our remarkable findings encourage further investigations in this and other mouse models for mitochondrial diseases. An interesting experiment would be, for example, to use a virus to express AOX in the sick tissues," Kallijärvi notes.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CRISPR-based gene editing shows promise in treating rare form of blindness